NASDAQ
40.01USD
-0.21 (-0.52%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5B
P/E
—
EPS
—
Beta
1.15
52W range
20.665-42.81
Day range
38.63–40.30
Open
39.01
Prev close
40.22
Volume
1.4M
Avg volume
1.9M
Dividend
0.64
IPO
2014-12-29
https://www.globenewswire.com/news-release/2026/08/03/3337317/0/en/Indivior-Reports-Second-Quarter-2026-Financial-Results-and-Raises-Full-Year-2026-Guidance.html · 8/3/2026+1.00
https://www.globenewswire.com/news-release/2026/08/03/3337311/19871/en/Supernus-Pharmaceuticals-and-Indivior-Pharmaceuticals-to-Merge-Creating-a-Diversified-CNS-Biopharmaceutical-Leader-with-Significant-Scale.html · 8/3/2026+0.80
https://www.zacks.com/stock/news/2947461/should-invesco-russell-2000-dynamic-multifactor-etf-omfs-be-on-your-investing-radar?cid=CS-STOCKNEWSAPI-FT-style_box_etf-2947461 · 7/3/2026+0.00
https://www.globenewswire.com/news-release/2026/06/22/3315028/0/en/Addex-Therapeutics-to-Report-2026-First-Quarter-Financial-Results-and-Host-Conference-Call-on-June-25-2026.html · 6/22/2026+0.20
https://www.fool.com/coverage/filings/2026/06/13/indivior-s-chief-scientific-officer-sold-over-18-000-company-shares-should-investors-worry/ · 6/14/2026+0.80
https://www.fool.com/coverage/filings/2026/05/30/what-to-know-about-this-fund-s-usd74-8-million-indivior-sale/ · 5/30/2026+0.80
https://www.fool.com/coverage/filings/2026/05/30/why-a-fund-made-a-usd143-million-bet-on-indivior-with-shares-up-a-staggering-200/ · 5/30/2026+0.90
https://www.zacks.com/commentary/2914771/best-momentum-stock-to-buy-for-may-5th?cid=CS-STOCKNEWSAPI-FT-zacks_1_rank_additions|momentum_additions-2914771 · 5/5/2026+1.00
https://www.globenewswire.com/news-release/2026/04/21/3277573/0/en/Addex-GABAB-PAM-Candidate-Demonstrates-Robust-Anti-Tussive-Activity-in-Non-Human-Primate-Chronic-Cough-Model.html · 4/21/2026+0.20
https://www.globenewswire.com/news-release/2026/03/11/3253803/0/en/New-Study-Shows-Adherence-to-Monthly-Injectable-Buprenorphine-Linked-to-Lower-Healthcare-Utilization-and-Costs-in-Opioid-Use-Disorder.html · 3/11/2026+0.80
https://www.defenseworld.net/2026/02/07/indivior-plc-nasdaqindv-given-consensus-rating-of-moderate-buy-by-analysts.html · 2/7/2026+0.60
https://www.prnewswire.com/news-releases/indivior-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-302620339.html · 11/19/2025+0.60
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
